XSPRAY PHARMA and Handa Therapeutics Enter Strategic Licensing Partnership for Advanced Therapeutic Development

“`html

Xspray Pharma Secures Licensing Deal With Handa Therapeutics

Published: November 27, 2023 at 8:00 AM PST

Updated: November 27, 2023 at 8:00 AM PST

Stockholm, Sweden – Xspray Pharma, a Pharmaceutical Company focused on improving drug formulations, has announced a significant licensing agreement with Handa Therapeutics. The Collaboration will focus on developing and commercializing an improved version of Dexloryx, a medication used to treat adults with schizophrenia.

The Agreement grants Xspray Pharma exclusive rights to develop, manufacture, and market an enhanced formulation of Dexloryx utilizing its proprietary NanoCrystal technology. This Technology aims to improve the drug’s bioavailability and potentially enhance its therapeutic effects. Handa Therapeutics will receive an upfront payment, milestone payments tied to development progress, and royalties on future sales.

“We are very pleased to partner with Handa Therapeutics on this vital project,” said Per Wågeus, CEO of Xspray Pharma. “Dexloryx is a valuable medication, and we believe our NanoCrystal technology can considerably improve its performance and benefit patients.”

The deal represents a key step for Xspray Pharma in expanding its portfolio of enhanced drug formulations. The Company’s NanoCrystal technology has the potential to address challenges associated with poorly soluble drugs, a common issue in the pharmaceutical industry. This Partnership underscores the growing demand for innovative drug delivery systems.

Handa Therapeutics expressed enthusiasm for the collaboration, highlighting Xspray pharma’s expertise in drug formulation and NanoCrystal technology. The Companies will work closely together to advance the development program and bring the improved Dexloryx formulation to market.

Understanding NanoCrystal Technology and its Impact on Pharmaceuticals

NanoCrystal technology represents a significant advancement in drug delivery. It involves reducing the size of drug particles to the nanoscale, increasing their surface area and improving their solubility. This can lead to enhanced bioavailability, faster absorption, and potentially reduced dosage requirements.

The benefits of NanoCrystal technology extend beyond improved drug performance. It can also enable the reformulation of existing drugs, extending their patent life and creating new market opportunities. Several Pharmaceutical companies are actively exploring NanoCrystal technology to address challenges associated with drug solubility and bioavailability.

The Pharmaceutical Industry is increasingly focused on developing innovative drug delivery systems to improve patient outcomes and address unmet medical needs. Technologies like NanoCrystal are playing a crucial role in this effort, offering the potential to transform the way drugs are formulated and administered.

Frequently Asked Questions About Xspray Pharma and Drug Formulation

1. what is Xspray Pharma’s core technology? Xspray Pharma specializes in NanoCrystal technology, a method for improving the bioavailability of drugs by reducing particle size.
2. What is dexloryx used for? Dexloryx is a medication used in the treatment of schizophrenia in adults.
3. How does NanoCrystal technology improve drug bioavailability? By reducing particle size, NanoCrystal technology increases the surface area of the drug, leading to faster dissolution and absorption.
4. What are milestone payments in a licensing agreement? Milestone payments are payments made to the licensor upon achieving specific development or regulatory milestones.
5. What is the potential benefit of this partnership for patients? The improved formulation of Dexloryx could offer enhanced therapeutic effects and potentially reduce side effects.
6. Is NanoCrystal technology widely used in the pharmaceutical industry? Yes, NanoCrystal technology is gaining increasing traction as a solution for improving the performance of poorly soluble drugs.
7. What does this agreement mean for Xspray Pharma’s future? This licensing deal expands Xspray Pharma’s portfolio and validates its NanoCrystal technology, positioning the company for further growth.

Disclaimer: this article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is indeed essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.

What are your thoughts on this new partnership? Share your comments below and let us know!